Wire · founder news, decoded · opportunities
FDA approves Sanofi's Sarclisa Escena, first anticancer treatment administered via on-body injector
FDA approves Sarclisa Escena, a subcutaneous formulation of Sanofi's multiple myeloma drug administered via Enable Injections' on-body injector, matching IV efficacy with shorter treatment time and fewer infusion-related reactions.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.
The Wire takeaway
If you're building drug-delivery devices, pharma giants now need you to solve the patient experience problem they've ignored for decades. Sanofi just proved that a simpler injector beats IV infusions on efficacy and comfort—that's a commercial template for every high-volume cancer therapy on the market.
Read the full story at pharmalive.com →
Topics: Digital Health · drug-delivery · on-body-injector · oncology · device-pharma · patient-experience